Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
Amgen on Wednesday announced that its phase 3 study involving ABP 959, a biosimilar candidate to eculizumab (Soliris), had met its primary endpoints in the DAHLIA study. The biosimilar is being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other indications.
In its statement, Amgen said that “ABP 959 has the same pharmaceutical form, dosage strength, route of administration, and dosing regimen” as the approved eculizumab in both the United States and the European Union.
Detailed results of this study will be presented at a future medical congress and submitted for publication.
PNH is a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis. This life-threatening disease brings about intravascular hemolytic anemia, bone marrow failure, and thromboembolic episodes. Patients experience arterial and venous thromboembolic episodes, visceral organ damage, rapid deterioration in quality of life, and increased mortality. Eculizumab is a monoclonal antibody that works by binding to a complementary protein to halt the mechanism that drive these effects.
DAHLIA was a phase 3, randomized, double-blind, active-controlled, 2-period crossover study in adult patients with PNH treated with eculizumab for at least 6 months. Patients were randomized 1:1 to receive the biosimilar or reference product in 1 of 2 sequences: (1) the biosimilar was given first, every 14 days for 52 weeks, followed by the reference product, every 14 days for 52 weeks; or (2) treatment followed the same schedule, except the reference product was given first. In the second treatment period, the switch occurred after 26 weeks, at week 79.
Results showed there as no clinically meaningful differences between ABP 959 and Soliris, based on control of intravascular hemolysis and measures of effectiveness at predefined time points, including when patients were switched from one product to the other.
“The safety and immunogenicity profile of ABP 959 was comparable to Soliris,” Amgen said in the statement.
"Today's positive results with ABP 959 demonstrate similar efficacy, safety and immunogenicity as the reference product, further highlighting Amgen's commitment to providing patients with access to high-quality, biologic therapies," said David M. Reese, MD, executive vice president of Research and Development at Amgen. "We look forward to working with regulators to make this potential biosimilar option available to patients."
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Equivalence Confirmed: CT-P41 Paves the Way for Affordable Osteoporosis Care
January 8th 2025Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME
January 6th 2025The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable efficacy, safety, pharmacokinetics, and immunogenicity at 24 weeks, with more long-term data expected.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.